0.00Open0.25Pre Close0 Volume36 Open Interest55.00Strike Price0.00Turnover160.59%IV27.10%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.0835Delta0.0220Gamma173.88Leverage Ratio-0.1330Theta0.0003Rho14.52Eff Leverage0.0067Vega
Janux Therapeutics Stock Discussion
$Merck & Co(MRK.US)$ already has an active partnership with $Janux Therapeutics(JANX.US)$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US)$ in which $Merck & Co(MRK.US)$ already has a seat at the table.
$Merck & Co(MRK.US)$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US)$
$Vaxcyte(PCVX.US)$
$Legend Biotech(LEGN.US)$
$Janux Therapeutics(JANX.US)$
$Aerovate(AVTE.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Evolent Health(EVH.US)$
$NewAmsterdam Pharma(NAMS.US)$
$RxSight(RXST.US)$
$TYRA BIOSCIENCES, INC.(TYRA.US)$
$Edgewise Therapeutics(EWTX.US)$
$4D Molecular Therapeutics(FDMT.US)$
$Biogen(BIIB.US)$
$PepGen(PEPG.US)$